Opioid-immune interactions in autism: Behavioural and immunological assessment during a double-blind treatment with naltrexone

Annali dell'Istituto Superiore di Sanita

Volumn 32, Issue 3, 1996, Pages 351-359

  Scifo, Renato ^a   Cioni, Matteo ^a   Nicolosi, Alfredo ^b   Batticane, Nunzio ^a   Tirolo, Cataldo ^a   Testa, Nuccio ^a   Quattropani, Maria C ^c   Morale, Maria C ^a   Gallo, Francesco ^d   Marchetti, Bianca ^d  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b CNR   (Italy)

^c INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

autism; immune function; naltrexone; opioid peptides

Indexed keywords

BETA ENDORPHIN; NALTREXONE; OPIATE; OPIATE ANTAGONIST; PLACEBO;

ADOLESCENT; ARTICLE; AUTISM; BEHAVIOR; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; ORAL DRUG ADMINISTRATION; SYMPTOMATOLOGY;

ADOLESCENT; ANTIGENS, CD; AUTISTIC DISORDER; BEHAVIOR; BETA-ENDORPHIN; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 12644317817     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. BLALOCK, J.E. 1994. Shared ligands and receptors as molecular mechanisms for communication between the immune and neuroendocrine systems. Ann. NY Acad. Sci. 741: 292-298.
2. JANKOVIC, B.D. 1994. Neuroimmunomodulation: from phenomenology to molecularevidence. Ann. NY Acad. Sci. 741: 11-38.
3. MAIER, S.F., WATKINS, L.R. & FLESHNER, M. 1994. Psychoneuroimmunology: the interface between behavior, brain and immunity. Am. Psychol. 49: 1004-1017.
4. MARCHETTI, B., PEIFFER, A., MORALE, M.C., BATTICANE, N., GALLO, F. & BARDEN, N. 1994. Transgenic animals with impaired type II glucocordcoid receptor gene expression: a model to study aging of the neuroendocrine immune system. Ann. NY Acad Sci. 719: 308-327.
5. MARCHETTI, B., MORALE, M.C., GALLO, F., BATTICANE, N., FARINELLA, Z. & CIONI, M. 1995. Neuroendocrineimmunology at the turn of the century : to wards a molecular understanding of basic mechanisms and implications for reproductive physiopathoiogy Endocrine 3: 845-861.
6. CARR, D.J.J. 1992. Neuroendocrine peptide receptors on cells of the Immune system. In: Neuroimmunoendocrinology. Chemical Immunology. Vol. 52. I.E. Blalock (Ed.). Karger, Basel, p. 84-99.
7. STEFANO, G.B. & SCHARRER, B. 1994. Endogenous morphine and related opiates, a new class of chemical messengers. Adv. Neuroimmunol. 4: 57-67.
8. MARCHETTI, B., SCIFO, R., BATTICANE, N. & SCAPAGNINI, U. 1990. Immunological significance of opioid peptide dysfunction in infantile autism. Brain Dysfunct. 3: 346-354.
9. MARCHETTI, B. & SCIFO, R. 1996. Autism and other brain disorders arising from a dysfunction of the opioid system in the neuroimmunological network. In: The international encyclopedia of pharmacology and therapeutics. Pergamon Press, New York, Oxford (in press).
10. WIBRAN, J., APPLEBOOM, T., FAMACY, J. & GOVAERTS, A. 1979. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal blood T lymphocytes. J. Immunol. 123: 1068-1070.
11. HARBOUR, D.V., SMITH, E.M. & BLALOCK, J.E. 1980. Splenic lymphocyte production of an endorphin during endotoxic shock. Brain Behav. Immunol. 1: 123-133.
12. SACERDOTE, P., RUBBOLI, F., LOCATELLI, L., CICILIATO, I.,MANTEGAZZA, P. & PANERAI, A.E. 1991. Pharmacological modulation of neuropeptides in peripheral mononuctear cells. J. Neuroimmunol. 32: 35-41.
13. FONTANA, L., FATTOROSSI, A., D'AMELIO, R., MIGLIORATI, A. & PERRICONE, R. 1987. Modulation of human concanavalin A-induced lymphocyte proliferative response by physiological concentrations of beta-endorphin. Immunopharmacology 13: 11-15.
14. SOLOMON, G.F., FIATARONE, M.A., BENTON, D., MORLEY, J.E., BLOOM, E. & MAKINODAN, T. 1988. Psychoimmunologic and endorphin function in the aged. In: Neuroimmuno-modulation: interventions in aging and cancer, Proceedings of the first Stromboli conference on aging and cancer. W. Pierpaoli & N.H. Spector (Eds). Ann. NY Acad. Sci. 521: 43-58.
15. PLOTNIKOFF, N.P. 1988. Opioids: immunomodulators a proposed role in cancer and aging. In: Neuroimmuno-modulation: interventions in aging and cancer, Proceedings of the first Stromboli conference on aging and cancer. W. Pierpaoli & N.H. Spector (Eds). Ann. NY Acad. Sci. 521: 312-322.
16. TESCHEMACHER, H., KOCH, G., SCHEFFLER, H., HILDEBRAND, A. & BRANTL, V. 1990. Opioid peptides: immunological significance. In: M.S. D'Orisio & A. Panerai (Eds). Ann. N.Y. Acad. Sci. 594: 66-77.
17. KALAT, J.W. 1978. Speculations on similarities between autism and opiate addiction (letter to the Editor). J. Autism Child. Schizophr. 8: 477-479.
18. PANKSEPP, J., HERMAN, B. & VILBERG, T. 1980. Endogenous opioids and social behavior. Neurosci. Biobehav. Rev. 4:473-487.
19. PANKSEPP, J. 1981. A neurochemical theory of autism. Trends Neurosci. 2: 174-177.
20. PANKSEPP, J. & LENSING, P. 1989. The theoretical and empirical basis for the opioid excess of early childhood autism. In: Proceedings of experimental psychology and the autistic syndromes. College St Hilde and St Bede, University of Durham. p. 113-128.
21. SAHLEY, T.L. & PANKSEPP, J. 1987. Brain opioids and autism: an updated analysis of possible linkages. J. Autism Devel. Disord. 17: 201-215.
22. SHATTOCK, P. 1989. The possible neuroregulatory role of peptides in autism. In: Proceedings of experimental psychology and the autistic syndrome. College St Hilde and St Bede, University of Durham, p. 129-146.
23. GILLBERG, C., TERENIUS, I. & LONNERHOLM, G. 1985. Endorphin activity in childhood psychosis. Arch. Gen. Psychiatry 42: 780-783.
24. GILLBERG, C. 1988. The role of endogenous opioids in autism and possible relationships to clinical features. In: Aspects of autism: biological research. L. Wing (Ed.). Gaskell, London, p. 101-128.
25. LEBOYER, M., BOUVARD, M. & DOUGAS, M. 1988. Effect of naltrexone on infantile autism (letter to the Editor). Lancet 26:715.
26. CHESS, S. 1977. Follow-up report on autism and congenital rubella. J. Autism Devel. Disord. 7: 69-81.
27. CRAWFORD, M.L., BURGE, D.R. & VANDERBEK, A.A. 1977. Depressed lymphocyteresponsiveness in autistic children. J. Autism Child. Schizopkr. 7: 49-55.
28. WEIZMAN, A., WEIZMAN, R., SZEKELY, G.A., WIJSENBEEK,H. & LIVNI, E. 1982. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am. J. Psychiatr. 7: 1462-1465.
29. TODD, R.D.& CIARANELLO, R.D. 1985. Demonstrations of intra-and interspecies differences in serotonin binding sites by antibodies from an autistic child. Proc. NatL Acad Sci. USA 82: 612-616.
30. STUBBS, E.G., RITVO, E.R. & MASON-BROTHERS, B.A. 1985. Autism and shared parental HLA antigens J. Am. Acad. Child Psychiatr. 24: 182-185.
31. SINGH, V.K., FUDENBERG, H.H., EMERSON, D. & COLEMAN, M. 1988. Immunodiagnosis and immunotherapy in autistic children. Ann. NY Acad. Sci. 540: 602-604.
32. +) T cells in autism. Immunol. Invest. 19: 245-251.
33. + helper T cell depression in autism. Immunol. Lett. 25: 341-346.
34. SINGH, V.K., WARREN, R.P , ODELL, J.D., WARREN, W.L. & COLE, P. 1993. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav. Immunol. 7: 97-103.
35. WARREN, R.P., FOSTER, A. & MARGARETTEN, N.C. 1987. Reduced natural killer cell activity in autism. J. Acad. Chil. Adol. Psychol. 26: 333-335.
36. WARREN, R.P., BURGER, R.A., ODELL, D., TORRES, A.R. & WARREN, W.L. 1994. Decreased plasma concentrations of the C4B complement protein in autism. Arch. Pediatr.Adolesc. Med. 148(2): 180-183.
37. HERMAN, B.H., HAMMOCK, M.K., ARTUR-SMITH, A., EGAN, J., CHATOOR, I., WERNER, A. & ZELNICK, N. 1987. Naltrexone decrease self-injurious behavior. Ann. Neurol. 22: 550-552.
38. CAMPBELL, M., PERRY, R., SMALL, A., MCVEIGH-TESCH, L. & CURREN, E. 1988. Naltrexone in infantile autism. Psychopharmacol. Bull. 21: 135-139.
39. CAMPBELL, M , ANDERSON, L.T , SMALL, A.M., ADAMS, P., GONZALES, N.M. & ERNST, M. 1993. Naltrexone in autistic children: behavioral symptoms and attentional learning. J. Am. Acad. Child. Adol. Psychiatry 32 (6):1283-1291.
40. SCIFO, R., BATTICANE, N., QUATTROPANI, M.C., SPOTO, G. & MARCHETTI, B. 1991. A double-blind trial with naltrexone in autism. Brain Dysfunct. 4: 301-307.
41. SCHOPLER, E., REICHLER, R.J. & ROCHEN RENNER, B. 1988. The childhood autism rating scale. Western Psychological Services, Los Angeles.
42. BARTHELEMY, C., ADRIEN, J.L., TANGUAY, P., GARREAU, B., FERMANIAN, J., ROUX, S., SAUVAGE, D. & LELORD, G. 1990. The behavioral summarized evaluation: validity and reliability of a scale for the assessment of the autistic behaviors. J. Autism Devel. Disord. 20: 189-201.
43. MORALE, M.C., BATTICANE, N., CIONI, M. & MARCHETTI, B. 1992. Up-regulation of beta-adrenergic receptors in Down's syndrome: a biological marker of neuro-immune deficit. Neuroimmunology 38: 1-14.
44. BATTICANE, N., MORALE, M.C., GALLO, F., FARINELLA, Z. & MARCHETTI, B. 1991. Luteinizing hormone-releasing hormone signaling at the lymphocyte involves stimulation of interleukin 2 receptor expression. Endocrinology 129: 277-286.
45. LENSING, P.J. 1990. Two single studies with naltrexone. In: Proceedings of experimental psychology and the autistic syndromes. College St Hilde and St Bede,University of Durham, p. 67-94.
46. MORIMOTO, C., STEINBERG, A.D, LETVIN, N.L., HAGAN, M., TAKEUCHI, T., DALEY, J., LEVINE, H. & SCHLOSSMAN, S .F. 1987. A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J. Clin. Invest. 79: 762-768.
47. MORIMOTO, C., HAFLER, D.A., WEINER, H.L., LETVIN, N., HAGAN, M., DAJLEY,J. & SCHLOSSMAN, S.F. 1987. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti 2H4 monoclonal activity. N. Engl. J. Med. 316: 67-72.
48. ANTEL, J., BROWN, M., NICHOLAS, M.K., BLAIN, M., NORHONA, A. & REDER, A. 1988. Activated suppressor cell function in multiple sclerosis: clinical correlations. J. Neuroimmunol. 17: 323-330.
49. + (helper inducer) cell increment suggest an activation of cell immune reactivity in multiple sclerosis. J. Neuroimmunol. 33: 97-102.
50. ZAGON, I.S., McLAUGHIN, P.J., WEAVER, D.J. & ZAGON, E. 1982. Opiate endorphins and the developing organism: a comprehensive bibliography. Neurosci. Biobehav. Rev. 6: 439-479.
51. GEE, A.L, THIELE, G.M. & JOHNSON,D R. 1994. Behaviorally conditioned modulation of natural killer cell activity: enhancement of baseline and activated natural killer cell activity. Int. J. Neurosci. 77: 139-152.
52. ZAGON, I.S. & MCLAUGHIN, P. Y. 1984. Naltrexone modulate body and brain development in rats: a role for endogenous opioid systems in growth. Life Sci. 35: 2057-2064.
53. ZAGON, I.S. & MCLAUGHIN, P. 1994. Opioids as determinants of brain development and plasticity. In: Neuropsychopharmacology. Proceedings of XIX Coll. Int. Neuropsychopharmacology, Washington, DC, 27 June - 1 July, (Suppl. part 1), vol. 10, No. 3S, p. 817S.